Searchable abstracts of presentations at key conferences in endocrinology

ea0055wb1 | Workshop B: Disorders of the hypothalamus and pituitary (II) | SFEEU2018

Gigantism presenting with visual failure

Stiles Craig E , Drake William M

A 22 year old man was referred to the endocrine unit at St Barts following an abnormal visual field test with his optician and subsequently with ophthalmology at Moorfields eye hospital. At presentation he was noted to be very tall (194 cm), with facial features of growth hormone excess. Despite starting puberty at the age of 12–13 he had experienced continued vertical growth - he was the tallest in his family and his parents had commented that he was continuing to grow, ...

ea0091oc5 | Oral Communications | SFEEU2023

The success story of Osilodrostat for optimisation of severe Cushing’s Disease

Subramaniam Yuvanaa , Dorward Neil , Drake William M , Brooke Antonia M

A 51-year-old gentleman presented in June 2022 with pneumobilia, staph liver abscesses and rapidly conducted atrial fibrillation requiring ITU admission. He had a 2-year history of typical Cushingoid features and hypogonadism, 4 agent hypertension since 2012, fragility fractures, previous renal calculi, pulmonary emboli and diabetes. He had not been able to walk unaided for a year (was mobilising with crutches on admission). In retrospect, he had previously had a cortisol of 7...

ea0015p238 | Pituitary | SFEBES2008

Successful use of once weekly pegvisomant administration in patients with acromegaly

Higham Claire , Thomas Julia , Drake Will M , Trainer Peter

Initial clinical trials with pegvisomant at doses of up to 80 mg once weekly led to a 30% fall in IGF-I. Subsequently, daily administration of up to 40 mg/day (280 mg/week) achieved an IGF-I within reference range in 97% of patients. Pegvisomant’s half-life is >70 h suggesting weekly dosing may be possible using higher doses than in the original trials.We performed a two-centre, open-label prospective study in seven patients (4M, 3F, mean age 57...

ea0048o1 | Oral Communications | SFEEU2017

40 years of hypoglycaemia and an adrenal mass

O'Toole Sam M , Turner Ben C , Plowman P Nick , Batterham Rachel L , Drake William M

Case History: A 69-year-old gentleman was admitted having lost consciousness. This episode was preceded by typical hypoglycaemic symptoms which, in retrospect, he had experienced for four decades with increasing frequency and severity over the past year. He was hypertensive. There was no family history of endocrinopathy or diabetes.Investigations: A supervised inpatient fast was undertaken along with cross-sectional and radio-isotope imaging.<p class...

ea0013p198 | Endocrine tumours and neoplasia | SFEBES2007

An unusual phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension

Davis Katherine , Khoo Bernard , Drake William M , Grossman Ashley B , Frankton Sarah

A 47 year old Macedonian Personal Trainer presented with 4 days of vomiting, abdominal pain and profuse sweating. He admitted abusing anabolic steroids 20 years previously but never insulin. The presenting capillary blood glucose (CBG) was 1.7 mmol/L, blood pressure (BP) 182/106 mmHg, pulse 62 bpm. On examination, he was sweaty, pale and cold. Blood was drawn for measurement of insulin, C-peptide, glucose, cortisol and thyroid function tests. He was treated with 50% dextrose a...

ea0036P11 | (1) | BSPED2014

The accuracy of 24-h urinary free cortisol as a screening test in the diagnosis of Cushing's syndrome in children

Shapiro Lucy , Elahi Shezan , Bailey Joe , Martin Lee , Drake William M , Savage Martin O , Storr Helen L

Background: Endogenous Cushing’s syndrome (CS) in children remains a challenge to diagnose and exclude. 24-h urinary free cortisol (UFC) measurements are a convenient, non-invasive test for paediatric patients.Objective: To assess the screening accuracy of 24-h UFC measurements in paediatric patients referred to our centre for evaluation of possible CS.Methods: A retrospective review of children referred to our centre between ...

ea0034p188 | Neoplasia, cancer and late effects | SFEBES2014

SDHB surveillance regime: a single UK institution experience

Srirangalingam Umasuthan , Khan Fazia , Gunganah Kirun , Sahdev Anju , Waterhouse Mona , Druce Maralyn R , Drake William M , Akker Scott A

Background: Succinate dehydrogenase B (SDHB) associated disease has been characterised by the presence of extra-adrenal paragangliomas with a high rate of metastatic transformation. There is currently no consensus as to the appropriate surveillance regimes for these subjects. We present the surveillance data from a single UK institution with an SDHB surveillance regime which includes annual MR imaging of the abdomen, biennial imaging of the neck, thorax and pelvis and annual u...

ea0030p2 | (1) | BSPED2012

Outcome of endoscopic transsphenoidal pituitary surgery in four paediatric Cushing's disease patients: a new therapeutic approach

Storr Helen L , Drake William M , Akker Scott A , Monson John P , Savage Martin O , Alusi Ghassan , Sabin H Ian

Selective transsphenoidal adenomectomy remains the accepted first line treatment for Cushing’s disease (CD), until recently by microscopic (sublabial) transsphenoidal pituitary surgery. Endonasal transsphenoidal endoscopic surgery is emerging as a novel, less invasive treatment for pituitary adenomas with lower postoperative complications and morbidity. The safety of endoscopic surgery has been extensively reviewed in adult patients and is now considered best practice for...

ea0025p3 | Bone | SFEBES2011

Evaluation of the association between serotonin and bone mineral density in patients with neuroendocrine tumours

Gupta Piya Sen , Drake William M , Akker Scott A , Chew Shern L , Grossman Ashley B , Druce Maralyn R

Introduction: Bone mineral density (BMD) and fracture tendency are influenced by diet, activity, drugs, and hormones. Recent studies highlight an inverse relationship between serotonin and BMD, of uncertain mechanism.Purpose: We investigated the relationship between serotonin metabolites and BMD in patients with sporadic neuroendocrine tumours (NETs), with and without the carcinoid syndrome.Materials and methods: One-year prospecti...

ea0015p328 | Steroids | SFEBES2008

Non-alcoholic fatty liver disease is associated with transcriptional dysregulation of 11β-hydroxysteroid dehydrogenase type 1 leading to excess intrahepatic glucocorticoid exposure

Coyle F M , Taylor N F , Feakins R , Monson J P , Drake W M , Foster G R

Background: Glucocorticoids play a key role in determining body fat distribution. Excess circulating glucocorticoids lead to intrahepatic fat accumulation. Obesity is associated with enhanced glucocorticoid production but this is offset by enhanced degradation such that circulating steroid concentrations are normal. However, tissue-specific pathways may lead to different degrees of cortisol exposure in different organs. Local steroid exposure in the liver is determined by the ...